Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model

Objective To evaluate the cost‐effectiveness of intravitreal bevacizumab to ranibizumab in patients with neovascular age‐related macular degeneration (AMD). Methods A cost‐utility analysis using a Markov model was performed to evaluate incremental cost‐effectiveness ratio [ICER, $US per quality‐ad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of evaluation in clinical practice 2012-04, Vol.18 (2), p.247-255
Hauptverfasser:	Patel, Jignesh J., Mendes, Margaret A.S., Bounthavong, Mark, Christopher, Melissa L.D., Boggie, Daniel, Morreale, Anthony P.
Format:	Artikel
Sprache:	eng
Schlagworte:	age-related macular degeneration Aged Aged, 80 and over Angiogenesis Inhibitors - economics Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Cost-Benefit Analysis cost-effectiveness analysis cost-utility analysis Female Humans Macular Degeneration - drug therapy Male Markov Chains Middle Aged Quality-Adjusted Life Years Ranibizumab United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!